Arkray‘s U.S. business has inked a licensing deal with Mellitus Health for its insulin titration software, Insulin Insights.
Mellitus Health, formerly known as Insulin Algorithms, developed the clinical decision-support tool to help doctors keep their patients’ blood sugar levels in control with optimized insulin therapy. The software is compatible with any blood glucose monitoring system and with all brands of insulin.
According to the deal, Arkray plans to integrate Insulin Insights into its suite of diabetes products.
“Mellitus Health’s software unlocks the value of glucose monitor data to make life easier for clinicians, save money for insurers and managed care providers, and—most importantly—improve health outcomes for patients using our Glucocard and ReliOn branded blood glucose meters,” Jonathan Chapman, President of Arkray USA, said in prepared remarks. “Our partnership with Mellitus Health has the potential to significantly improve diabetes clinical care.”
“We designed Insulin Insights to address the diabetes care gap, which is the failure of health care systems to meet the clinical needs of the growing diabetic population,” Mellitus Health CEO Josh Davidson added.
“Ninety percent of diabetics are treated by primary care physicians because of the massive shortage of endocrinologists. Insulin Insights mitigates this problem by giving these and other clinicians, including nurses and physician assistants, the ability to provide the regular insulin dose adjustments needed to maintain blood sugar control. We look forward to working with Arkray as they share our vision of improving the care of the diabetic patient by creating an end-to-end solution from patient to clinician.”
